NCT02240290 - Study to Evaluate the Absorption, Distribution, Break Down and Elimination and the Safety of 14C-Labeled Tozadenant | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions

N/A, as Healthy Volunteers

Interventions

DRUG

tozadenant tablet

Active substance: tozadenant Pharmaceutical form: Tablet Concentration: 240 mg Route of Administration: Oral administration

DRUG

C14-tozadenant capsule

Active substance: C14-tozadenant Pharmaceutical form: Capsule Concentration: 74 kBq (2 μCi) Route of administration: Oral administration

Trial Locations (1)

Pharmaceutical Research Associates Group B.V., Zuidlaren